Is the use of Bisolvan (bromhexine) and Trazesil lozenges (benzydamine) safe in pregnancy?

Safety of Bisolvan (Bromhexine) and Trazesil (Benzydamine) Lozenges in Pregnancy

Both Bisolvan (bromhexine) and Trazesil lozenges (benzydamine) have limited safety data in pregnancy, but based on available evidence, mucolytics like bromhexine can be continued during pregnancy when clinically necessary, while benzydamine lozenges appear reasonably safe based on small prospective studies showing no increased risk of malformations.

Bromhexine (Bisolvan) - The Mucolytic Component

Guideline-Based Recommendations

The 2020 ERS/TSANZ Task Force statement on airways diseases in pregnancy provides the most relevant framework 1. This guideline emphasizes that for women with bronchiectasis and cystic fibrosis, routine therapy with mucolytics should continue to maintain maternal stability throughout pregnancy. The guideline explicitly states that maintaining maternal respiratory health outweighs theoretical fetal risks when the mother requires these medications.

Key Principles from Guidelines:

• Maternal disease control is paramount - untreated respiratory disease poses documented risks to the fetus through maternal hypoxia
• Mucolytics are part of routine maintenance therapy that should be continued
• The risk-benefit calculation favors treatment when maternal respiratory function requires it

Clinical Context:

While bromhexine is not specifically named in the guidelines, it falls within the mucolytic class that guidelines recommend continuing. The evidence suggests bromhexine has been used extensively with a reasonable safety profile 2, though specific pregnancy data remains limited.

Benzydamine (Trazesil Lozenges) - The Anti-inflammatory Component

Available Safety Data

Important clarification: The FDA drug labels provided 3 are for trazodone (an antidepressant), NOT benzydamine/Trazesil. These are completely different medications and should not be confused.

For actual benzydamine lozenges, a 2002 prospective controlled study provides the most direct evidence 4. This study examined 54 women exposed to throat lozenges (including benzydamine-containing products) during first trimester:

• Major malformations: 3.84% in exposed group vs 3.92% in controls (no significant difference, RR 0.98)
• No increase in spontaneous abortions or decreased birthweight
• Study concluded these lozenges were not associated with increased risk

Limitations to Consider:

• Small sample size (54 women)
• Study authors acknowledged larger studies needed for confirmation
• Limited to first trimester exposure data

Practical Clinical Algorithm

When to Use These Medications:

For Bromhexine (Bisolvan):

1. Continue if already taking for chronic respiratory conditions (bronchiectasis, CF, chronic bronchitis)
2. Can initiate if maternal respiratory function requires mucolytic therapy
3. Prioritize maternal oxygenation - hypoxia from undertreated respiratory disease poses known fetal risks

For Benzydamine Lozenges (Trazesil):

1. Reasonable option for symptomatic relief of oropharyngeal inflammation/pain when needed
2. Short-term use preferred - use for acute symptoms rather than prolonged courses
3. Consider alternatives first: Saline gargles, acetaminophen for pain (which has established pregnancy safety)

Risk Stratification by Trimester:

First Trimester (Organogenesis):

• Greatest theoretical concern for structural malformations
• Benzydamine data from 4 shows no increased risk, but limited sample
• Use only when maternal benefit clearly justifies use

Second/Third Trimester:

• Lower concern for structural defects
• Focus shifts to maternal respiratory stability
• Mucolytics more clearly justified if needed for maternal disease control

Important Caveats and Pitfalls

Common Misconceptions:

1. Do not confuse trazodone with Trazesil - completely different medications with different risk profiles
2. "Natural" does not mean safer - evaluate all medications systematically
3. Undertreated maternal disease carries real fetal risk - maternal hypoxia from respiratory disease is documented to harm the fetus 1

What to Avoid:

According to rhinosinusitis guidelines 5:

• Oral decongestants should NOT be used (risk of gastroschisis, hypertension)
• First-generation antihistamines should be avoided (sedative/anticholinergic effects)
• Safer alternatives include saline rinses and topical corticosteroid nasal sprays

Monitoring Considerations:

• Document clear maternal indication for therapy
• Use lowest effective dose for shortest duration needed
• Monitor maternal respiratory status - deterioration poses greater fetal risk than medication
• Consider pregnancy registry enrollment if available for post-market surveillance

The Bottom Line

Bromhexine can be continued or initiated when maternal respiratory disease requires mucolytic therapy, following the principle that maternal disease control protects fetal outcomes 1. Benzydamine lozenges appear reasonably safe based on limited prospective data 4, though should be reserved for situations where symptomatic relief is genuinely needed rather than routine use. The overarching principle is that untreated maternal respiratory compromise poses documented fetal risks that often exceed theoretical medication risks.